title: Long-term treatment with aspirin desensitization: a prospective clinical trial comparing 100 and 300 mg aspirin daily.
abstract: BACKGROUND
  The daily dose of aspirin in desensitization in aspirin-sensitive asthmatics with nasal polyps is still a matter of debate.
  
  
  OBJECTIVE
  To compare two doses of aspirin during the first year of desensitization and to evaluate long-term effects on nasal/pulmonary symptoms.
  
  
  METHODS
  Patients with positive aspirin provocation test were treated with either 100 or 300 mg aspirin daily.
  
  
  RESULTS
  In all patients taking 100 mg aspirin (n = 7) recurrent nasal polyps were observed. No patient experienced reduction of asthma medication or improvement of pulmonary function. In the 300 mg group no recurrent nasal polyps were seen. Asthma medication could be reduced in three patients, pulmonary function was improved in five patients. Thirty-nine consecutively desensitized patients, taking 300 mg aspirin, showed significant improvement of olfaction and polyp-free nasal passages during the first year of therapy. After a median follow-up of 27 months no sinus revision surgery was necessary.
  
  
  CONCLUSIONS
  Aspirin desensitization followed by 300 mg aspirin daily is efficacious and results in polyp-free nasal airways, improvement of sense of smell, and reduction of the need for sinus revision surgery for recurrent nasal polyps. Aspirin in a dose of 100 mg daily is not sufficient to effectively reduce nasal and bronchial or pulmonary symptoms and to prevent recurrent nasal polyps by at least the first 12 months of treatment.
authors.affiliation: Department of Otorhinolaryngology, University of Ulm, Ulm, Germany.
authors.forename: A
authors.initials: A
authors.lastname: Rozsasi
authors.forename: D
authors.initials: D
authors.lastname: Polzehl
authors.forename: T
authors.initials: T
authors.lastname: Deutschle
authors.forename: E
authors.initials: E
authors.lastname: Smith
authors.forename: K
authors.initials: K
authors.lastname: Wiesmiller
authors.forename: H
authors.initials: H
authors.lastname: Riechelmann
authors.forename: T
authors.initials: T
authors.lastname: Keck
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage* / Q000009:adverse effects; D001241:Aspirin / Q000008:administration & dosage* / Q000009:adverse effects; D001249:Asthma / Q000139:chemically induced / Q000276:immunology / Q000628:therapy*; D003888:Desensitization, Immunologic; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009298:Nasal Polyps / Q000628:therapy*; D012008:Recurrence; D012129:Respiratory Function Tests; D013997:Time Factors; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D001241:Aspirin